A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2008
At a glance
- Drugs Budesonide; Budesonide/formoterol; Formoterol
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SEEDLING
- Sponsors AstraZeneca
- 12 Jun 2008 New trial record.
- 04 Jun 2008 sNAD submitted to FDA according to AstraZeneca media release.
- 04 Jun 2008 Efficacy and safety results were reported at ATS 2008.